Table 1.
Characteristics of participants, sputum, and the number of sequences analyzed.
| [0, 2–6]Clinical Characteristics and Blood Values | [0, 7–9]Sputum Analyses* | |||||||
|---|---|---|---|---|---|---|---|---|
| [0, 4–5]Plasma HIV-1 RNA determinations during ART |
HIV-1 DNA copies per 106 CD4+ in PBMC | # of Sputum Cells (× 106) Collected | Macrophage to Lymphocyte Ratio in Sputum, (Bloodc) | HIV-1 DNA copies per 106 Macrophages and Lymphocytes | ||||
| Participant | ART Regimena | Years on ART | # >50/>400 copies/mL | Total # | ||||
| B1 | A | 7.1 | 0/0 | 40 | 194 | 52 | 3.5 (0.17) | 156 |
| B2 | A | 6.2 | 3/0 | 31 | 593 | 21 | 3.2 (0.26) | 165 |
| C1 | A | 7.0 | 0/0 | 22 | 126 | 11 | 5.2 (0.16) | 342 |
| F1 | A | 3.8 | 5/0 | 30 | 1163 | 4 | 7.7 (0.34) | 27 |
| I2 | B | 1.5 | 0/0 | 8 | 614 | 38 | 5.0 (0.19) | 18 |
| J1 | B | 4.2 | 2/0 | 23 | 451 | 19 | 21.3 (0.20) | 13.3 |
| L1 | A | 7.1 | 2/0 | 37 | 262 | 5 | 4.7 (0.29) | 230 |
| R1 | B | 6.6 | 1/0 | 25 | 228 | 16 | >100:1 (0.42) | 90 |
| S3 | A | 1.6 | 0/0 | 15 | 116 | 3 | >100:1 (0.21) | 20 |
| S4 | A | 0.8 | 3/0 | 21 | 764 | 2 | 20.0 (0.23) | 5 |
| V1 | A | 5.8 | 1/0 | 31 | 2314 | 38 | 15.4 (0.16) | 79 |
| Median | 5.8 | 1/0 | 25 | 451 | 16 | 7.7 (0.21) | 79 | |
| Total | 17/0 | 283 | ||||||
ART, antiretroviral therapy; PBMC, peripheral blood mononuclear cells.
*
Included a median of 34.5% (range 5 – 70.5%) squamous epithelial cells and 29% (range 3 – 82%) neutrophils.
a
Antiretoviral Regimens: A = three class combination with nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitor, and protease inhibitor; B = two class combination with nucleoside reverse transcriptase inhibitors and protease inhibitors (lopinavir with ritonavir).
b
estimated by QUALITY program [29] applied to limiting dilution PCR of env.
c
ratio of monocytes to lymphocyes in the concomitant peripheral blood.